Pediatrics & Therapeutics
Open Access

Maternal Blood Parameters and Risk of Neonatal Pathological Jaundice: Understanding the Relation

Joseph Gigante^{* *}Correspondence: Joseph Gigante, Department of Pediatrics, St Christopher’s Hospital for Children, Philadelphia, USA, Email:

Author info »

Description

Jaundice is a common condition in newborns that occurs due to the accumulation of bilirubin in the blood, leading to yellowing of the skin and eyes. While physiological jaundice is a normal process in newborns, pathological jaundice can be a sign of an underlying condition and requires medical attention. Recent research has shown that maternal blood parameters may play a role in the development of neonatal pathological jaundice.

Pathological jaundice is a more severe form of jaundice that occurs in up to 10% of newborns. It is usually caused by an underlying medical condition such as blood group incompatibility, infections, or metabolic disorders. Pathological jaundice typically requires medical treatment, as high levels of bilirubin can cause brain damage if left untreated.

Maternal blood parameters and risk of neonatal pathological jaundice

Recent studies have suggested that maternal blood parameters may be a significant factor in the development of neonatal pathological jaundice. Maternal blood parameters, such as blood group, Rh factor, and hemoglobin levels, can affect the transfer of bilirubin from the mother to the fetus and increase the risk of jaundice in the newborn.

Blood group and Rh factor: Blood group and Rh factor play a crucial role in the development of neonatal pathological jaundice. If the mother's blood type is incompatible with the baby's blood type, the mother's immune system may produce antibodies that attack the baby's red blood cells, leading to hemolysis and the release of excess bilirubin into the blood. This condition is known as Hemolytic Disease of the Newborn (HDN) and can cause severe jaundice, anemia, and other complications.

Hemoglobin levels: Maternal hemoglobin levels have also been linked to the development of neonatal pathological jaundice.

Low maternal hemoglobin levels can lead to decreased oxygen delivery to the fetus, causing anemia in the newborn. Anemic newborns are at higher risk of developing jaundice, as the breakdown of red blood cells releases excess bilirubin into the blood.

Other factors: Other maternal blood parameters, such as glucose levels, white blood cell count, and liver function tests, may also be linked to the risk of neonatal pathological jaundice. High maternal glucose levels have been associated with an increased risk of neonatal jaundice, while abnormal liver function tests may indicate liver disease or other conditions that can affect the metabolism of bilirubin.

Prevention and treatment of neonatal pathological jaundice typically involve identifying and treating the underlying cause of the condition. In cases of HDN, treatment may involve blood transfusions, phototherapy, or exchange transfusions to remove excess bilirubin from the blood. Infections and metabolic disorders may require specific medical treatments and close monitoring.

Maternal blood parameters may also be monitored during pregnancy to identify potential risk factors for neonatal jaundice. Regular prenatal care, including blood tests and ultrasound exams, can help detect and manage conditions that may affect the fetus's health.

In conclusion, maternal blood parameters play an essential role in the development of neonatal pathological jaundice. Blood group, Rh factor, hemoglobin levels, and other factors can affect the transfer of bilirubin from the mother to the fetus and increase the risk of jaundice in the newborn. Early identification and treatment of risk factors can help prevent and manage neonatal jaundice, reducing the risk of complications and improving outcomes for both mother and baby.